Search research articles
Contact Us
Filters
Showing results (141-150 of 206) with videos related to
Page
of 21
Sort By:
Pediatric Blood & Cancer
|
November 27, 2025
Determining Preclinical Safety of Aclarubicin in Pediatric Malignancies
Darleen S Tu, Aaron K Olson, Kimberly S Waggie, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
September 13, 2014
Prostate adenocarcinomas aberrantly expressing p63 are molecularly distinct from usual-type prostatic adenocarcinomas
Hsueh-Li Tan, Michael C Haffner, David M Esopi, et al.
The Prostate
|
August 17, 2021
Phenotypic characterization of two novel cell line models of castration-resistant prostate cancer
Michael C Haffner, Akshay Bhamidipati, Harrison K Tsai, et al.
Optics Express
|
May 14, 2015
Plasmonic-organic hybrid (POH) modulators for OOK and BPSK signaling at 40 Gbit/s
A Melikyan, K Koehnle, M Lauermann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 17, 2020
Regulation of CEACAM5 and Therapeutic Efficacy of an Anti-CEACAM5-SN38 Antibody-drug Conjugate in Neuroendocrine Prostate Cancer
Diana C DeLucia, Thomas M Cardillo, Lisa Ang, et al.
The American Journal of Surgical Pathology
|
June 15, 2018
PD-L1 Assays 22C3 and SP263 are Not Interchangeable in Non-Small Cell Lung Cancer When Considering Clinically Relevant Cutoffs: An Interclone Evaluation by Differently Trained Pathologists
Enrico Munari, Giulio Rossi, Giuseppe Zamboni, et al.
Cancer & Metabolism
|
September 28, 2018
CD38 is methylated in prostate cancer and regulates extracellular NAD<sup></sup>
Jack Mottahedeh, Michael C Haffner, Tristan R Grogan, et al.
Cells
|
April 26, 2024
Development and Characterisation of a New Patient-Derived Xenograft Model of AR-Negative Metastatic Castration-Resistant Prostate Cancer
Daniel J Turnham, Manisha S Mullen, Nicholas P Bullock, et al.
Journal for Immunotherapy of Cancer
|
July 1, 2021
TGM4: an immunogenic prostate-restricted antigen
Zoila A Lopez-Bujanda, Aleksandar Obradovic, Thomas R Nirschl, et al.
Biorxiv : the Preprint Server for Biology
|
July 29, 2024
Molecular consequences of acute versus chronic CDK12 loss in prostate carcinoma nominates distinct therapeutic strategies
Sander Frank, Thomas Persse, Ilsa Coleman, et al.
Page
of 21
Search research articles
Search
Showing results (141-150 of 206) with videos related to
Sort By:
Page
of 21
Pediatric Blood & Cancer
|
November 27, 2025
Determining Preclinical Safety of Aclarubicin in Pediatric Malignancies
Darleen S Tu, Aaron K Olson, Kimberly S Waggie, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
September 13, 2014
Prostate adenocarcinomas aberrantly expressing p63 are molecularly distinct from usual-type prostatic adenocarcinomas
Hsueh-Li Tan, Michael C Haffner, David M Esopi, et al.
The Prostate
|
August 17, 2021
Phenotypic characterization of two novel cell line models of castration-resistant prostate cancer
Michael C Haffner, Akshay Bhamidipati, Harrison K Tsai, et al.
Optics Express
|
May 14, 2015
Plasmonic-organic hybrid (POH) modulators for OOK and BPSK signaling at 40 Gbit/s
A Melikyan, K Koehnle, M Lauermann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 17, 2020
Regulation of CEACAM5 and Therapeutic Efficacy of an Anti-CEACAM5-SN38 Antibody-drug Conjugate in Neuroendocrine Prostate Cancer
Diana C DeLucia, Thomas M Cardillo, Lisa Ang, et al.
The American Journal of Surgical Pathology
|
June 15, 2018
PD-L1 Assays 22C3 and SP263 are Not Interchangeable in Non-Small Cell Lung Cancer When Considering Clinically Relevant Cutoffs: An Interclone Evaluation by Differently Trained Pathologists
Enrico Munari, Giulio Rossi, Giuseppe Zamboni, et al.
Cancer & Metabolism
|
September 28, 2018
CD38 is methylated in prostate cancer and regulates extracellular NAD<sup></sup>
Jack Mottahedeh, Michael C Haffner, Tristan R Grogan, et al.
Cells
|
April 26, 2024
Development and Characterisation of a New Patient-Derived Xenograft Model of AR-Negative Metastatic Castration-Resistant Prostate Cancer
Daniel J Turnham, Manisha S Mullen, Nicholas P Bullock, et al.
Journal for Immunotherapy of Cancer
|
July 1, 2021
TGM4: an immunogenic prostate-restricted antigen
Zoila A Lopez-Bujanda, Aleksandar Obradovic, Thomas R Nirschl, et al.
Biorxiv : the Preprint Server for Biology
|
July 29, 2024
Molecular consequences of acute versus chronic CDK12 loss in prostate carcinoma nominates distinct therapeutic strategies
Sander Frank, Thomas Persse, Ilsa Coleman, et al.
Page
of 21